Acumen Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 2830 acumenpharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Mar 31st, 2026 7:35 am
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Mar 30th, 2026 7:40 am
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Mar 27th, 2026 6:30 am
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... - Mar 26th, 2026 1:00 pm
Acumen Pharmaceuticals Q4 Earnings Call Highlights - Mar 26th, 2026 8:07 am
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - Mar 26th, 2026 5:00 am
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - Mar 19th, 2026 2:00 pm
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - Mar 18th, 2026 6:11 pm
Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Mar 17th, 2026 3:41 pm
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - Mar 17th, 2026 6:00 am
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - Mar 16th, 2026 4:30 am
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Mar 10th, 2026 2:00 pm
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - Mar 3rd, 2026 6:00 am
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Jan 27th, 2026 7:08 pm
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Jan 26th, 2026 3:06 am
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - Jan 25th, 2026 4:05 am
January 2026's Rising Stars: Top Penny Stocks To Watch - Jan 19th, 2026 11:05 am
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Dec 2nd, 2025 6:00 am
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Nov 28th, 2025 11:05 am
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Nov 18th, 2025 6:00 am